J
Jonathan M. Niloff
Researcher at Harvard University
Publications - 31
Citations - 5596
Jonathan M. Niloff is an academic researcher from Harvard University. The author has contributed to research in topics: Ovarian cancer & Carcinoma. The author has an hindex of 21, co-authored 31 publications receiving 5482 citations. Previous affiliations of Jonathan M. Niloff include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
Robert C. Bast,Thomas L. Klug,E St John,Eric Jenison,Jonathan M. Niloff,Herbert Lazarus,Ross S. Berkowitz,T. Leavitt,C.T. Griffiths,Leroy M. Parker,Vincent R. Zurawski,Robert C. Knapp +11 more
TL;DR: Determination of CA 125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer, and rising or falling levels ofCA 125 correlated with progression or regression of disease in 42 of 45 instances.
Journal ArticleDOI
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
Robert C. Bast,Thomas L. Klug,Elena S. St. John,Eric Jenison,Jonathan M. Niloff,Herbert Lazarus,Ross S. Berkowtiz,T. Leavitt,C. Thomas Griffiths,Leroy M. Parker,Vincent R. Zurawski,Robert C. Knapp +11 more
TL;DR: Determination of CA 125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer, and rising or falling levels ofCA 125 correlated with progression or regression of disease in 42 of 45 instances.
Journal ArticleDOI
Cancer of the Uterine Cervix
TL;DR: Invasive cervical cancer is uncommon in the United States, with an incidence of 15,800 cases and 4800 deaths in 1995; this relatively low incidence is largely due to the effectiveness of screening programs that assess cervical cytology by Pap smear.
Journal Article
Monoclonal Antibody Immunoradiometric Assay for an Antigenic Determinant (CA 125) Associated with Human Epithelial Ovarian Carcinomas
TL;DR: The ability of researchers, with this assay, to discriminate between CA 125 values in sera of patients with ovarian carcinoma and those of healthy individuals and patients with benign disease suggests that the assay deserves continued evaluation for monitoring and early diagnosis of ovarian cancer.
Journal ArticleDOI
Elevated serum concentrations of CA-125 in patients with advanced endometriosis.
Robert L. Barbieri,Jonathan M. Niloff,Robert C. Bast,E. Scaetzl,R. W. Kistner,Robert C. Knapp +5 more
TL;DR: Serum CA-125 concentrations were elevated in patients with stage III or IV endometriosis, compared with controls with negative diagnostic laparoscopies, and Immunocytochemical techniques demonstrated the presence of CA- 125 on the cell surface of endometiotic lesions.